7 results on '"Sever MŞ"'
Search Results
2. Helicobacter pyloriantibodies in hemodialysis patients and renal transplant recipients
- Author
-
Yıldız, A, primary, Beşışık, F, additional, Akkaya, V, additional, Sever, MŞ, additional, Bozfakıoğlu, S, additional, Yılmaz, G, additional, and Ark, E, additional
- Published
- 1999
- Full Text
- View/download PDF
3. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients.
- Author
-
Yıldız, A, Beşışık, F, Akkaya, V, Sever, MŞ, Bozfakıoğlu, S, Yılmaz, G, and Ark, E
- Subjects
HELICOBACTER pylori infections ,HELICOBACTER diseases ,GASTROINTESTINAL diseases ,KIDNEY transplantation - Abstract
In this cross-sectional, controlled study, Helicobacter pylori (H. pylori) infection, a probable factor in the development of gastrointestinal problems, was investigated in dialysis patients and renal transplant recipients. Forty-seven dialysis patients (22 male, 25 female, mean age of 36.6±15 yr (range 18–83 yr)), 57 renal transplant recipients (39 male, 18 female, mean age of 36.8±10 yr (range 19–60 yr)) and 55 healthy individuals (34 male, 21 female, mean age of 33.4±9.6 yr (range 21–58 yr)) were included and no significant difference was found in the study groups. The mean time spent on dialysis in the hemodialysis group was 32.5±27.7 months (range 1–100 months). H. pylori antibodies were detected in 22 of 57 (38.6%) patients in the transplantation group, 31 of 47 (65.9%) patients in the dialysis group and 39 of 55 (72.5%) in the control group. No correlation was found between H. pylori infection and age, sex, primary disease, frequency of dialysis, duration and type of transplantation and the immunosuppressive therapy. However, patients with H. pylori antibodies spent a shorter time on dialysis compared to patients without the antibodies (26.6±23.5 vs 44.1±32.1 months, p=0.038). The frequency of H. pylori infection in the transplantation group was significantly lower than the control and dialysis groups (p<0.01). This finding may be explained on the basis of decreased humoral antibody response to H. pylori infection, secondary to immunosuppressive therapy rather than decreased incidence of infection in the transplantation group. Finally, we concluded that the value of the serological test for diagnosis of H. pylori infection should be interpreted cautiously in these patient groups. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
4. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community
- Author
-
Patrik Finne, Elena Zakharova, Christoph Wanner, Raymond Vanholder, María José Soler, Inga Arūnė Bumblytė, Ziad A. Massy, Halima Resić, Bénédicte Stengel, Annette Bruchfeld, Kitty J Jager, Vladimír Tesař, Mario Cozzolino, Kate Stevens, Peter J. Blankestijn, Goce Spasovski, Mehmet Sukru Sever, Ivan Rychlik, Myftar Barbullushi, Carmine Zoccali, Andrzej Wiecek, Dimitris Goumenos, Jérôme Harambat, Institut Català de la Salut, [Sever MŞ] Department of Nephrology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey. [Jager KJ] ERA-EDTA Registry, Department of Medical Informatics, Amsterdam Public Health Research Institute Amsterdam, Noord-Holland, The Netherlands. [Vanholder R] Nephrology Section, Department of Internal Medicine and Pediatrics, University Hospital Ghent, Gent, Belgium. European Kidney Health Alliance (EKHA), Brussels, Belgium. [Stengel B] UVSQ, University Paris-Saclay, University Paris-Sud, Inserm, Clinical Epidemiology Team, CESP, Villejuif, France. [Harambat J] UVSQ, University Paris-Saclay, University Paris-Sud, Inserm, Clinical Epidemiology Team, CESP, Villejuif, France. Pediatric Nephrology Unit, Bordeaux University Hospital, Bordeaux, France. [Finne P] Helsinki University Central Hospital, Division of Nephrology, Helsinki, 00029, Finland. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Department of Medicine, Clinicum, Nefrologian yksikkö, HUS Abdominal Center, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and University of Milan
- Subjects
Nephrology ,030232 urology & nephrology ,Psychological intervention ,Environmental pollution ,Disease ,0302 clinical medicine ,ENVIRONMENTAL-POLLUTION ,DISPARITIES ,Health care ,Urologi och njurmedicin ,Medicine and Health Sciences ,030212 general & internal medicine ,Otros calificadores::/terapia [Otros calificadores] ,3. Good health ,PREVALENCE ,Eastern european ,Medicina - Investigació ,CARDIOVASCULAR-DISEASE ,POPULATION-BASED SURVEY ,HEALTH ,Insuficiència renal crònica - Tractament ,chronic renal failure ,CKD ,dialysis ,ESRD ,kidney transplantation ,técnicas de investigación::métodos::diseño de la investigación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,medicine.medical_specialty ,AWARENESS ,Insuficiència renal crònica - Prevenció ,03 medical and health sciences ,Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic::Kidney Failure, Chronic [DISEASES] ,Internal medicine ,Investigative Techniques::Methods::Research Design [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine ,Urology and Nephrology ,AcademicSubjects/MED00340 ,CKJ Reviews ,Transplantation ,business.industry ,Other subheadings::/therapy [Other subheadings] ,medicine.disease ,3126 Surgery, anesthesiology, intensive care, radiology ,Family medicine ,RISK-FACTORS ,enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica::fallo renal crónico [ENFERMEDADES] ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,CHRONIC RENAL-DISEASE ,business ,Kidney disease - Abstract
Chronic renal failure; Dialysis; Kidney transplantation Insuficiència renal crònica; Diàlisi; Trasplantament de ronyó Insuficiencia renal crónica; Diálisis; Trasplante de riñón Chronic kidney disease (CKD) is a major health problem because of its high prevalence, associated complications and high treatment costs. Several aspects of CKD differ significantly in the Eastern European nephrology community compared with Western Europe because of different geographic, socio-economic, infrastructure, cultural and educational features. The two most frequent aetiologies of CKD, DM and hypertension, and many other predisposing factors, are more frequent in the Eastern region, resulting in more prevalent CKD Stages 3–5. Interventions may minimize the potential drawbacks of the high prevalence of CKD in Eastern Europe, which include several options at various stages of the disease, such as raising public, medical personnel and healthcare authorities awareness; early detection by screening high-risk populations; preventing progression and CKD-related complications by training health professionals and patients; promoting transplantation or home dialysis as the preferred modality; disseminating and implementing guidelines and guided therapy and encouraging/supporting country-specific observational research as well as international collaborative projects. Specific ways to significantly impact CKD-related problems in every region of Europe through education, science and networking are collaboration with non-nephrology European societies who have a common interest in CKD and its associated complications, representation through an advisory role within nephrology via national nephrology societies, contributing to the training of local nephrologists and stimulating patient-oriented research. The latter is mandatory to identify country-specific kidney disease–related priorities. Active involvement of patients in this research via collaboration with the European Kidney Patient Federation or national patient federations is imperative to ensure that projects reflect specific patient needs. The treatment of kidney failure is costly, therefore financial support from governments is essential to ensure that all patients receive appropriate treatment. This imposes a major burden on the economy. According to the World Bank, only 74% of governments in Eastern and Central Europe provide full support for KRT [7]. Funding of treatment in earlier stages of CKD is even more problematic because of the high number of patients and because the diagnosis may not be made in a timely manner. Although no objective data are available, it is very likely that public funding at earlier stages of CKD is less common or, at least, less comprehensive than reimbursement of KRT.
- Published
- 2021
- Full Text
- View/download PDF
5. Disaster preparedness for people with kidney disease and kidney healthcare providers.
- Author
-
Sever MŞ, Vanholder R, and Lameire N
- Subjects
- Humans, Kidney Diseases therapy, Disaster Planning organization & administration, Health Personnel
- Abstract
Purpose of Review: Man-made and natural disasters become more frequent and provoke significant morbidity and mortality, particularly among vulnerable people such as patients with underlying kidney diseases. This review summarizes strategies to minimize the risks associated with mass disasters among kidney healthcare providers and patients affected by kidney disease., Recent Findings: Considering patients, in advance displacement or evacuation are the only options to avoid harmful consequences of predictable disasters such as hurricanes. Following unpredictable catastrophes, one can only rely upon educational initiatives for disaster risk mitigation. Preparatory initiatives before disasters such as training courses should target minimizing hazards in order to decrease morbidity and mortality by effective interventions during and early after disasters. Retrospective evaluation of previous interventions is essential to identify adverse consequences of disaster-related health risks and to assess the efficacy of the medical response. However, preparations and subsequent responses are always open for ameliorations, even in well developed countries that are aware of disaster risks, and even after predictable disasters., Summary: Adverse consequences of disasters in patients with kidney diseases and kidney healthcare providers can be mitigated by predisaster preparedness and by applying action plans and pragmatic interventions during and after disasters. Preparing clear, practical and concise recommendations and algorithms in various languages is mandatory., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community.
- Author
-
Sever MŞ, Jager KJ, Vanholder R, Stengel B, Harambat J, Finne P, Tesař V, Barbullushi M, Bumblytė IA, Zakharova E, Spasovski G, Resic H, Wiecek A, Blankestijn PJ, Bruchfeld A, Cozzolino M, Goumenos D, Soler MJ, Rychlík I, Stevens KI, Wanner C, Zoccali C, and Massy ZA
- Abstract
Chronic kidney disease (CKD) is a major health problem because of its high prevalence, associated complications and high treatment costs. Several aspects of CKD differ significantly in the Eastern European nephrology community compared with Western Europe because of different geographic, socio-economic, infrastructure, cultural and educational features. The two most frequent aetiologies of CKD, DM and hypertension, and many other predisposing factors, are more frequent in the Eastern region, resulting in more prevalent CKD Stages 3-5. Interventions may minimize the potential drawbacks of the high prevalence of CKD in Eastern Europe, which include several options at various stages of the disease, such as raising public, medical personnel and healthcare authorities awareness; early detection by screening high-risk populations; preventing progression and CKD-related complications by training health professionals and patients; promoting transplantation or home dialysis as the preferred modality; disseminating and implementing guidelines and guided therapy and encouraging/supporting country-specific observational research as well as international collaborative projects. Specific ways to significantly impact CKD-related problems in every region of Europe through education, science and networking are collaboration with non-nephrology European societies who have a common interest in CKD and its associated complications, representation through an advisory role within nephrology via national nephrology societies, contributing to the training of local nephrologists and stimulating patient-oriented research. The latter is mandatory to identify country-specific kidney disease-related priorities. Active involvement of patients in this research via collaboration with the European Kidney Patient Federation or national patient federations is imperative to ensure that projects reflect specific patient needs., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Effects of acetaminophen and mannitol on crush injuries in rats: An experimental study.
- Author
-
Çelikmen MF, Sarıkaya S, Özüçelik DN, Sever MŞ, Açıksarı K, Çelikmen DM, Yazıcıoğlu M, Kandemir A, Doğan H, Ayvacı BM, Özaşır Abuşka D, and Sadıllıoğlu S
- Subjects
- Acetaminophen administration & dosage, Acetaminophen pharmacology, Acute Kidney Injury blood, Alanine Transaminase blood, Analgesics, Non-Narcotic administration & dosage, Analgesics, Non-Narcotic pharmacology, Animals, Crush Syndrome blood, Diuretics, Osmotic administration & dosage, Diuretics, Osmotic pharmacology, Diuretics, Osmotic therapeutic use, Kidney drug effects, Male, Mannitol administration & dosage, Mannitol pharmacology, Mannitol therapeutic use, Rats, Rats, Sprague-Dawley, Acetaminophen therapeutic use, Acute Kidney Injury prevention & control, Analgesics, Non-Narcotic therapeutic use, Crush Syndrome drug therapy, Disease Models, Animal
- Abstract
Background: The present objective was to evaluate effects of acetaminophen and mannitol on renal function and histopathology in crush injuries., Methods: Thirty-six rats weighing 370-400 g each were used. No surgery was performed on the first (control) group. The gastrocnemius muscle regions of each rat in the remaining 5 groups were compressed for 2 or 24 hours. In the 4th group, 100 mg/kg acetaminophen was intraperitoneally administered. In the 5th group, 1 g/kg mannitol was administered. In the 6th group, 100 mg/kg acetaminophen and 1 g/kg mannitol were administered., Results: No statistically significant differences were observed among the treatment groups in terms of sodium, potassium, alanine aminotransferase (ALT), and average creatinine clearance values. Hydropic degeneration, tubular necrosis, presence of immunoperoxidase and myoglobin, tubulus epithelial cell degeneration, and presence of PAS-dyed material in tubular lumen was more prominently decreased in the acetaminophen group than the mannitol group. Improvement was observed in the group that was administered both drugs, compared to the mannitol-only group, though findings were still worse than those of the group administered acetaminophen only., Conclusion: In crush injuries, acetaminophen improves histopathological renal damage better than mannitol. When used in conjunction with mannitol, the toxic effect of acetaminophen on the liver is decreased.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.